Lv12
90 积分 2023-08-08 加入
Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature
1天前
待确认
Updated results from the phase Ib/II study of fruquintinib combined with SOX and toripalimab in patients with advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC)
16天前
已完结
Carcinoid syndrome presenting as diffuse violaceous cutaneous flushing
22天前
已完结
HSR25-198: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Hand-Foot Skin Reaction (HFSR) or Palmar-Plantar Erythrodysesthesia (PPE) in Patients With Cancers Treated With Fruquintinib
29天前
已关闭
A Multicenter Phase II Study of Locoregional Gemcitabine Combined with Surufatinib and Camrelizumab in FGFR2 Non-Altered Intrahepatic Cholangiocarcinoma
1个月前
已关闭
Correction to: Clinical research progress of fruquintinib in the treatment of malignant tumors
1个月前
已完结
Fruquintinib-associated posterior reversible encephalopathy syndrome in a patient with multiply metastatic rectal cancer
1个月前
已完结
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study
2个月前
已完结
EV344/#770 Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial
2个月前
已关闭
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
3个月前
已完结
皖公网安备34019202002308
